Natus Medical Incorporated (NASDAQ:BABY) Files An 8-K Completion of Acquisition or Disposition of Assets

Natus Medical Incorporated (NASDAQ:BABY) Files An 8-K Completion of Acquisition or Disposition of Assets
Item 2.01.

Story continues below

Completion of Acquisition or Disposition of Assets

On October 6, 2017, Natus Medical Incorporated (the “Company”) completed the acquisition of certain neurosurgery business assets from Integra LifeSciences ("Integra") that was announced on September 11, 2017. The acquisition includes the global Camino ICP monitoring product line, including its San Diego manufacturing facility, and the U.S. rights relating to Integra's fixed pressure shunts, as well as U.S. rights to Codman's DURAFORM® dural graft implant, standard EVD catheters and CSF collection systems.

On October 6, 2017, the Company issued a press release announcing the completion of the acquisition of certain neurosurgery assets from Integra. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

Item 2.01.

Financial Statements and Exhibits

(d) Exhibits.

ExhibitNo.

Description

99.1

Press release dated October 6, 2017 announcing the completion of the acquisition.


NATUS MEDICAL INC Exhibit
EX-99.1 2 a2017-integralifesciencesa.htm EXHIBIT 99.1 Exhibit Natus Completes Acquisition of Neurosurgery Assets from Integra LifeSciencesPLEASANTON,…
To view the full exhibit click here

About Natus Medical Incorporated (NASDAQ:BABY)

Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders. The Company’s segment is neurology and newborn care product families. Its product offerings include computerized neurodiagnostic systems for audiology, neurology, polysomnography, and neonatology, as well as newborn care products, such as hearing screening systems, phototherapy devices for the treatment of newborn jaundice, head-cooling products for the treatment of brain injury in newborns, incubators to control the newborn’s environment, and software systems for managing and tracking disorders and diseases for public health laboratories. It is organized into two strategic business units: Neurology and Newborn Care.

An ad to help with our costs